Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis

Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic naïve patie...

Full description

Saved in:
Bibliographic Details
Published in:BMC psychiatry 2018-08, Vol.18 (1), p.246-246, Article 246
Main Authors: Petruzzelli, Maria Giuseppina, Margari, Mariella, Peschechera, Antonia, de Giambattista, Concetta, De Giacomo, Andrea, Matera, Emilia, Margari, Francesco
Format: Article
Language:English
Subjects:
Adolescence
Analysis
Antipsychotic agents
Antipsychotics
Blood glucose
Child development
Clinical high risk of psychosis
Complications and side effects
Diabetes
Dopamine
Dosage and administration
Drug therapy
Glucose
Glucose tolerance
Homeostasis
Hyperprolactinemia
Hypotheses
Insulin
Insulin resistance
Lipids
Metabolic syndrome
Neuroendocrine dysfunctions
Patient outcomes
Pediatrics
Physiological aspects
Prolactin regulation
Psychiatry
Psychosis
Psychotic disorders
Psychotropic drugs
Risk factors
Schizophrenia
Schizophrenia spectrum psychosis
Teenagers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c560t-954f6cd6f265605cec137d78d71687bf00d5ddab0e989b585dc6e583ef6c050f3
cites cdi_FETCH-LOGICAL-c560t-954f6cd6f265605cec137d78d71687bf00d5ddab0e989b585dc6e583ef6c050f3
container_end_page 246
container_issue 1
container_start_page 246
container_title BMC psychiatry
container_volume 18
creator Petruzzelli, Maria Giuseppina
Margari, Mariella
Peschechera, Antonia
de Giambattista, Concetta
De Giacomo, Andrea
Matera, Emilia
Margari, Francesco
description Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic naïve patients with first episode psychosis (FEP), rising the hypothesis that schizophrenia itself may be related to an abnormal regulation of prolactin secretion and to impaired glucose tolerance. The aim of this study was to compare prolactin levels, glycometabolism parameters and lipid profile between a sample of 31 drug-naive adolescents in the acute phase of FEP and a control group of 23 subjects at clinical high risk (CHR) of developing psychosis. The assessment involved anthropometric data (weight, height, BMI index, pubertal stage) and blood tests (levels of glucose, glycated hemoglobin, serum insulin, triglycerides, total and fractionated cholesterol, prolactin). Insulin resistance (IR) was calculated through the homeostatic model of assessment (HOMA-IR), assuming a cut-off point of 3.16 for adolescent population. FEP patients and CHR controls were compared by using Student's t-distribution (t-test) for parametric data. P 
doi_str_mv 10.1186/s12888-018-1827-3
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_0fdc1d8cdd3e4f8bb176f0dc76f3b4dc</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A556986615</galeid><doaj_id>oai_doaj_org_article_0fdc1d8cdd3e4f8bb176f0dc76f3b4dc</doaj_id><sourcerecordid>A556986615</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-954f6cd6f265605cec137d78d71687bf00d5ddab0e989b585dc6e583ef6c050f3</originalsourceid><addsrcrecordid>eNptklFvFCEUhSdGY2v1B_hiSHzxZSrMDAzzYtI01jZp4osmvhEGLrtsZmEEpmb_vXe7tXaNIYHh8p0zuXCq6i2j54xJ8TGzRkpZUyZrJpu-bp9Vp6zrWd103Y_nT75Pqlc5byhlveTsZXXSUipkM7DTyl_vZkhzipM2xQfYek10sMSHvEw-kATZ56KDASwRm5YVCdrfAZl18RBKJr98WRPQadqRGDIU4nzKhcDsc7TI5Z1ZRzR5Xb1wesrw5mE9q75fff52eV3ffv1yc3lxWxsuaKkH3jlhrHCNwD03YFjb217angnZj45Sy63VI4VBDiOX3BoBXLaAKsqpa8-qm4OvjXqj5uS3Ou1U1F7dF2JaKZ2KNxMo6qxhVhprW-icHEfWC0etwbkdO2vQ69PBa17GLViDDSc9HZkenwS_Vqt4pwQd6CA6NPjwYJDizwVyUVufDUyTDhCXrBoqGwSHjiL6_h90E5cU8Kr21CBFx6X8S600NuCDi_hfszdVF5wLxATjSJ3_h8Jh8YFNDOA81o8E7CAwKeacwD32yKjaZ00dsqYwa2qfNdWi5t3Ty3lU_AlX-xuYwtG0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2089864588</pqid></control><display><type>article</type><title>Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis</title><source>PubMed Central (Open Access)</source><source>Publicly Available Content Database</source><creator>Petruzzelli, Maria Giuseppina ; Margari, Mariella ; Peschechera, Antonia ; de Giambattista, Concetta ; De Giacomo, Andrea ; Matera, Emilia ; Margari, Francesco</creator><creatorcontrib>Petruzzelli, Maria Giuseppina ; Margari, Mariella ; Peschechera, Antonia ; de Giambattista, Concetta ; De Giacomo, Andrea ; Matera, Emilia ; Margari, Francesco</creatorcontrib><description>Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic naïve patients with first episode psychosis (FEP), rising the hypothesis that schizophrenia itself may be related to an abnormal regulation of prolactin secretion and to impaired glucose tolerance. The aim of this study was to compare prolactin levels, glycometabolism parameters and lipid profile between a sample of 31 drug-naive adolescents in the acute phase of FEP and a control group of 23 subjects at clinical high risk (CHR) of developing psychosis. The assessment involved anthropometric data (weight, height, BMI index, pubertal stage) and blood tests (levels of glucose, glycated hemoglobin, serum insulin, triglycerides, total and fractionated cholesterol, prolactin). Insulin resistance (IR) was calculated through the homeostatic model of assessment (HOMA-IR), assuming a cut-off point of 3.16 for adolescent population. FEP patients and CHR controls were compared by using Student's t-distribution (t-test) for parametric data. P &lt; 0.05 was considered significant. Significant higher level of prolactin was found in FEP group than in CHR group (mean = 28.93 ± 27.16 vs 14.29 ± 7.86, P = 0.009), suggesting a condition of hyperprolactinemia (HPRL). Patients with FEP were more insulin resistant compared to patients at CHR, as assessed by HOMA-IR (mean = 3.07 ± 1.76 vs 2.11 ± 1.11, P = 0.043). Differences of fasting glucose (FEP = 4.82 ± 0.71, CHR = 4.35 ± 0.62, P = 0.016) and HbA1c (FEP = 25.86 ± 13.31, CHR = 33.00 ± 2.95, P = 0.013), were not clinically significant as the mean values were within normal range for both groups. No significant differences were found for lipid profile. A BMI value within the range of normal weight was found for both groups, with no significant differences. We suggested that HPRL, increase in HOMA-IR, and psychotic symptoms may be considered different manifestations of the acute onset of schizophrenia spectrum psychosis, with a common neurobiological vulnerability emerging since adolescence. The influence of age and gender on clinical manifestations of psychotic onset should be considered for early prevention and treatment of both schizophrenia spectrum psychosis and neuroendocrine-metabolic dysfunctions.</description><identifier>ISSN: 1471-244X</identifier><identifier>EISSN: 1471-244X</identifier><identifier>DOI: 10.1186/s12888-018-1827-3</identifier><identifier>PMID: 30068291</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adolescence ; Analysis ; Antipsychotic agents ; Antipsychotics ; Blood glucose ; Child development ; Clinical high risk of psychosis ; Complications and side effects ; Diabetes ; Dopamine ; Dosage and administration ; Drug therapy ; Glucose ; Glucose tolerance ; Homeostasis ; Hyperprolactinemia ; Hypotheses ; Insulin ; Insulin resistance ; Lipids ; Metabolic syndrome ; Neuroendocrine dysfunctions ; Patient outcomes ; Pediatrics ; Physiological aspects ; Prolactin regulation ; Psychiatry ; Psychosis ; Psychotic disorders ; Psychotropic drugs ; Risk factors ; Schizophrenia ; Schizophrenia spectrum psychosis ; Teenagers</subject><ispartof>BMC psychiatry, 2018-08, Vol.18 (1), p.246-246, Article 246</ispartof><rights>COPYRIGHT 2018 BioMed Central Ltd.</rights><rights>Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s). 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-954f6cd6f265605cec137d78d71687bf00d5ddab0e989b585dc6e583ef6c050f3</citedby><cites>FETCH-LOGICAL-c560t-954f6cd6f265605cec137d78d71687bf00d5ddab0e989b585dc6e583ef6c050f3</cites><orcidid>0000-0003-1734-788X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090964/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2089864588?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30068291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Petruzzelli, Maria Giuseppina</creatorcontrib><creatorcontrib>Margari, Mariella</creatorcontrib><creatorcontrib>Peschechera, Antonia</creatorcontrib><creatorcontrib>de Giambattista, Concetta</creatorcontrib><creatorcontrib>De Giacomo, Andrea</creatorcontrib><creatorcontrib>Matera, Emilia</creatorcontrib><creatorcontrib>Margari, Francesco</creatorcontrib><title>Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis</title><title>BMC psychiatry</title><addtitle>BMC Psychiatry</addtitle><description>Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic naïve patients with first episode psychosis (FEP), rising the hypothesis that schizophrenia itself may be related to an abnormal regulation of prolactin secretion and to impaired glucose tolerance. The aim of this study was to compare prolactin levels, glycometabolism parameters and lipid profile between a sample of 31 drug-naive adolescents in the acute phase of FEP and a control group of 23 subjects at clinical high risk (CHR) of developing psychosis. The assessment involved anthropometric data (weight, height, BMI index, pubertal stage) and blood tests (levels of glucose, glycated hemoglobin, serum insulin, triglycerides, total and fractionated cholesterol, prolactin). Insulin resistance (IR) was calculated through the homeostatic model of assessment (HOMA-IR), assuming a cut-off point of 3.16 for adolescent population. FEP patients and CHR controls were compared by using Student's t-distribution (t-test) for parametric data. P &lt; 0.05 was considered significant. Significant higher level of prolactin was found in FEP group than in CHR group (mean = 28.93 ± 27.16 vs 14.29 ± 7.86, P = 0.009), suggesting a condition of hyperprolactinemia (HPRL). Patients with FEP were more insulin resistant compared to patients at CHR, as assessed by HOMA-IR (mean = 3.07 ± 1.76 vs 2.11 ± 1.11, P = 0.043). Differences of fasting glucose (FEP = 4.82 ± 0.71, CHR = 4.35 ± 0.62, P = 0.016) and HbA1c (FEP = 25.86 ± 13.31, CHR = 33.00 ± 2.95, P = 0.013), were not clinically significant as the mean values were within normal range for both groups. No significant differences were found for lipid profile. A BMI value within the range of normal weight was found for both groups, with no significant differences. We suggested that HPRL, increase in HOMA-IR, and psychotic symptoms may be considered different manifestations of the acute onset of schizophrenia spectrum psychosis, with a common neurobiological vulnerability emerging since adolescence. The influence of age and gender on clinical manifestations of psychotic onset should be considered for early prevention and treatment of both schizophrenia spectrum psychosis and neuroendocrine-metabolic dysfunctions.</description><subject>Adolescence</subject><subject>Analysis</subject><subject>Antipsychotic agents</subject><subject>Antipsychotics</subject><subject>Blood glucose</subject><subject>Child development</subject><subject>Clinical high risk of psychosis</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Dopamine</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Glucose</subject><subject>Glucose tolerance</subject><subject>Homeostasis</subject><subject>Hyperprolactinemia</subject><subject>Hypotheses</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Lipids</subject><subject>Metabolic syndrome</subject><subject>Neuroendocrine dysfunctions</subject><subject>Patient outcomes</subject><subject>Pediatrics</subject><subject>Physiological aspects</subject><subject>Prolactin regulation</subject><subject>Psychiatry</subject><subject>Psychosis</subject><subject>Psychotic disorders</subject><subject>Psychotropic drugs</subject><subject>Risk factors</subject><subject>Schizophrenia</subject><subject>Schizophrenia spectrum psychosis</subject><subject>Teenagers</subject><issn>1471-244X</issn><issn>1471-244X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptklFvFCEUhSdGY2v1B_hiSHzxZSrMDAzzYtI01jZp4osmvhEGLrtsZmEEpmb_vXe7tXaNIYHh8p0zuXCq6i2j54xJ8TGzRkpZUyZrJpu-bp9Vp6zrWd103Y_nT75Pqlc5byhlveTsZXXSUipkM7DTyl_vZkhzipM2xQfYek10sMSHvEw-kATZ56KDASwRm5YVCdrfAZl18RBKJr98WRPQadqRGDIU4nzKhcDsc7TI5Z1ZRzR5Xb1wesrw5mE9q75fff52eV3ffv1yc3lxWxsuaKkH3jlhrHCNwD03YFjb217angnZj45Sy63VI4VBDiOX3BoBXLaAKsqpa8-qm4OvjXqj5uS3Ou1U1F7dF2JaKZ2KNxMo6qxhVhprW-icHEfWC0etwbkdO2vQ69PBa17GLViDDSc9HZkenwS_Vqt4pwQd6CA6NPjwYJDizwVyUVufDUyTDhCXrBoqGwSHjiL6_h90E5cU8Kr21CBFx6X8S600NuCDi_hfszdVF5wLxATjSJ3_h8Jh8YFNDOA81o8E7CAwKeacwD32yKjaZ00dsqYwa2qfNdWi5t3Ty3lU_AlX-xuYwtG0</recordid><startdate>20180801</startdate><enddate>20180801</enddate><creator>Petruzzelli, Maria Giuseppina</creator><creator>Margari, Mariella</creator><creator>Peschechera, Antonia</creator><creator>de Giambattista, Concetta</creator><creator>De Giacomo, Andrea</creator><creator>Matera, Emilia</creator><creator>Margari, Francesco</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1734-788X</orcidid></search><sort><creationdate>20180801</creationdate><title>Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis</title><author>Petruzzelli, Maria Giuseppina ; Margari, Mariella ; Peschechera, Antonia ; de Giambattista, Concetta ; De Giacomo, Andrea ; Matera, Emilia ; Margari, Francesco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-954f6cd6f265605cec137d78d71687bf00d5ddab0e989b585dc6e583ef6c050f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adolescence</topic><topic>Analysis</topic><topic>Antipsychotic agents</topic><topic>Antipsychotics</topic><topic>Blood glucose</topic><topic>Child development</topic><topic>Clinical high risk of psychosis</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Dopamine</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Glucose</topic><topic>Glucose tolerance</topic><topic>Homeostasis</topic><topic>Hyperprolactinemia</topic><topic>Hypotheses</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Lipids</topic><topic>Metabolic syndrome</topic><topic>Neuroendocrine dysfunctions</topic><topic>Patient outcomes</topic><topic>Pediatrics</topic><topic>Physiological aspects</topic><topic>Prolactin regulation</topic><topic>Psychiatry</topic><topic>Psychosis</topic><topic>Psychotic disorders</topic><topic>Psychotropic drugs</topic><topic>Risk factors</topic><topic>Schizophrenia</topic><topic>Schizophrenia spectrum psychosis</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Petruzzelli, Maria Giuseppina</creatorcontrib><creatorcontrib>Margari, Mariella</creatorcontrib><creatorcontrib>Peschechera, Antonia</creatorcontrib><creatorcontrib>de Giambattista, Concetta</creatorcontrib><creatorcontrib>De Giacomo, Andrea</creatorcontrib><creatorcontrib>Matera, Emilia</creatorcontrib><creatorcontrib>Margari, Francesco</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Petruzzelli, Maria Giuseppina</au><au>Margari, Mariella</au><au>Peschechera, Antonia</au><au>de Giambattista, Concetta</au><au>De Giacomo, Andrea</au><au>Matera, Emilia</au><au>Margari, Francesco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis</atitle><jtitle>BMC psychiatry</jtitle><addtitle>BMC Psychiatry</addtitle><date>2018-08-01</date><risdate>2018</risdate><volume>18</volume><issue>1</issue><spage>246</spage><epage>246</epage><pages>246-246</pages><artnum>246</artnum><issn>1471-244X</issn><eissn>1471-244X</eissn><abstract>Hyperprolactinemia and glucose and lipid metabolism abnormalities are often found in patients with schizophrenia and are generally considered secondary to the use of antipsychotic drugs. More recent studies have shown these same neuroendocrine and metabolic abnormalities in antipsychotic naïve patients with first episode psychosis (FEP), rising the hypothesis that schizophrenia itself may be related to an abnormal regulation of prolactin secretion and to impaired glucose tolerance. The aim of this study was to compare prolactin levels, glycometabolism parameters and lipid profile between a sample of 31 drug-naive adolescents in the acute phase of FEP and a control group of 23 subjects at clinical high risk (CHR) of developing psychosis. The assessment involved anthropometric data (weight, height, BMI index, pubertal stage) and blood tests (levels of glucose, glycated hemoglobin, serum insulin, triglycerides, total and fractionated cholesterol, prolactin). Insulin resistance (IR) was calculated through the homeostatic model of assessment (HOMA-IR), assuming a cut-off point of 3.16 for adolescent population. FEP patients and CHR controls were compared by using Student's t-distribution (t-test) for parametric data. P &lt; 0.05 was considered significant. Significant higher level of prolactin was found in FEP group than in CHR group (mean = 28.93 ± 27.16 vs 14.29 ± 7.86, P = 0.009), suggesting a condition of hyperprolactinemia (HPRL). Patients with FEP were more insulin resistant compared to patients at CHR, as assessed by HOMA-IR (mean = 3.07 ± 1.76 vs 2.11 ± 1.11, P = 0.043). Differences of fasting glucose (FEP = 4.82 ± 0.71, CHR = 4.35 ± 0.62, P = 0.016) and HbA1c (FEP = 25.86 ± 13.31, CHR = 33.00 ± 2.95, P = 0.013), were not clinically significant as the mean values were within normal range for both groups. No significant differences were found for lipid profile. A BMI value within the range of normal weight was found for both groups, with no significant differences. We suggested that HPRL, increase in HOMA-IR, and psychotic symptoms may be considered different manifestations of the acute onset of schizophrenia spectrum psychosis, with a common neurobiological vulnerability emerging since adolescence. The influence of age and gender on clinical manifestations of psychotic onset should be considered for early prevention and treatment of both schizophrenia spectrum psychosis and neuroendocrine-metabolic dysfunctions.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>30068291</pmid><doi>10.1186/s12888-018-1827-3</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1734-788X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-244X
ispartof BMC psychiatry, 2018-08, Vol.18 (1), p.246-246, Article 246
issn 1471-244X
1471-244X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_0fdc1d8cdd3e4f8bb176f0dc76f3b4dc
source PubMed Central (Open Access); Publicly Available Content Database
subjects Adolescence
Analysis
Antipsychotic agents
Antipsychotics
Blood glucose
Child development
Clinical high risk of psychosis
Complications and side effects
Diabetes
Dopamine
Dosage and administration
Drug therapy
Glucose
Glucose tolerance
Homeostasis
Hyperprolactinemia
Hypotheses
Insulin
Insulin resistance
Lipids
Metabolic syndrome
Neuroendocrine dysfunctions
Patient outcomes
Pediatrics
Physiological aspects
Prolactin regulation
Psychiatry
Psychosis
Psychotic disorders
Psychotropic drugs
Risk factors
Schizophrenia
Schizophrenia spectrum psychosis
Teenagers
title Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A54%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hyperprolactinemia%20and%20insulin%20resistance%20in%20drug%20naive%20patients%20with%20early%20onset%20first%20episode%20psychosis&rft.jtitle=BMC%20psychiatry&rft.au=Petruzzelli,%20Maria%20Giuseppina&rft.date=2018-08-01&rft.volume=18&rft.issue=1&rft.spage=246&rft.epage=246&rft.pages=246-246&rft.artnum=246&rft.issn=1471-244X&rft.eissn=1471-244X&rft_id=info:doi/10.1186/s12888-018-1827-3&rft_dat=%3Cgale_doaj_%3EA556986615%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c560t-954f6cd6f265605cec137d78d71687bf00d5ddab0e989b585dc6e583ef6c050f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2089864588&rft_id=info:pmid/30068291&rft_galeid=A556986615&rfr_iscdi=true